The potential of both Nintedanib, a clinically approved TKI for lung adenocarcinoma, and an investigational dual anti-VEGF/Ang2 nanobody (BI 836880) to prevent the occurrence of clinically relevant BM was investigated. This evidence concerns the gene ANGPT2 and lung adenocarcinoma.